Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

A hidden route for ovarian cancer spread?

NCT ID NCT06237582

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study investigates whether lymph nodes in the lower abdomen, called the inferior epigastric lymph node basin, might be an early stop for ovarian cancer spreading from the peritoneum. Researchers will biopsy these nodes in 20 patients undergoing surgery for ovarian peritoneal metastases to see how often they contain cancer cells. The goal is to understand if this pathway could serve as a marker for how the disease progresses and its risk of spreading further.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
epigastric lymph node biopsy
What this could lead to
If this pathway is confirmed, it could lead to better prediction of how ovarian cancer spreads and possibly new ways to prevent systemic metastasis.
What could go wrong
This is a small, early study with only 20 participants, so findings may not apply broadly. The procedure is invasive and carries surgical risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Jun 2022

Finished

Sep 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who will undergo complete cytoreductive surgery for peritoneal metastases from ovarian origin Exclusion Criteria: * Minor patients * Patients unable to give written informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinomatosis, peritoneal are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Institut Jules Bordet

    Brussels, 1070, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.